- Candel Therapeutics (CADL, Financial) showcases promising results from its phase 1b trial, sparking investor interest.
- Analyst forecasts suggest a significant upside potential for CADL, with price targets varying significantly.
- Despite positive analyst sentiment, GuruFocus' GF Value projects a notable downside.
Candel Therapeutics (CADL) has recently shared encouraging news from its phase 1b trial. The study, which evaluated the efficacy of combining CAN-2409 with nivolumab and standard high-grade glioma treatments, reported enhanced survival rates and immune system activation. These promising outcomes present a potential for broader application across various solid tumors.
Wall Street Analysts Forecast
Wall Street analysts have set their sights on Candel Therapeutics Inc (CADL, Financial), offering a one-year average price target of $21.00. Projections range from a high of $25.00 to a low of $15.00, indicating substantial potential growth of 341.18% from the current share price of $4.76. Investors can explore more detailed analyst predictions on the Candel Therapeutics Inc (CADL) Forecast page.
The consensus among four brokerage firms positions Candel Therapeutics Inc (CADL, Financial) with an average recommendation of 1.5, which translates to a "Buy" rating. This rating is part of a scale from 1 to 5, where 1 means a Strong Buy and 5 indicates a Sell recommendation.
GuruFocus GF Value Estimate
While analyst sentiment is optimistic, GuruFocus presents a different perspective. The estimated GF Value for Candel Therapeutics Inc (CADL, Financial) is projected at $0.80 in one year, predicting a significant downside of 83.19% from the current trading price of $4.76. GF Value is a GuruFocus proprietary metric that assesses the fair value of a stock, taking into account historical trading multiples, past business growth, and future performance estimates. For a deeper dive, visit the Candel Therapeutics Inc (CADL) Summary page.
